Purpose

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned pembrolizumab monotherapy.

Condition

Eligibility

Eligible Ages
Between 18 Years and 100 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Participant is ≥ 18 years of age - The participant provides written informed consent for the trial - Participant is willing to comply with all study procedures for the duration of the study - Subject has tumor biomarkers that are EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) negative - Participant is a NSCLC subject prescribed pembrolizumab monotherapy per standard of care - Participant is diagnosed with brain metastases that meet the RANO-BM criteria for measurable disease: [MR contrast-enhancing lesion measured in at least one dimension with a minimum size of 10mm, visible on 2 or more axial slices that are 5 mm or less apart with 0 mm skip (preferably < 1.5mm apart with 0 mm skip). The perpendicular diameter should measure at least 5 mm] - Participant has a Karnofsky Performance Status ≥ 70% and/or ECOG 0-2 - Participant may have up to 3 device-accessible MR visible Brain Metastases - Female subject is confirmed NOT PREGNANT each procedure day. Male and Female subjects are utilizing highly effective contraception during the study and through 120 days (4 months) after the study - Screening/Baseline laboratory values

Exclusion Criteria

  • Subject is pregnant or breastfeeding, - Participant has evidence of acute intracranial hemorrhage or significant calcifications in the focused ultrasound sonication beam path - Participant has metastatic melanoma or other tissue histology at risk for spontaneous intracranial hemorrhage in natural history - Participant has signs and symptoms of increased intracranial pressure or symptomatic mass effect, midline shift or evidence of subfalcine, uncal or tonsillar herniation - Participant receiving Bevacizumab (Avastin) therapy, or other drugs with a proclivity for causing bleeding - History of bleeding disorder, coagulopathy or with a history of spontaneous brain tumor hemorrhage, anticoagulation or antiplatelet therapy or medication known to increase the risk of hemorrhage within washout period prior to treatment (i.e., antiplatelet or vitamin K inhibitor anticoagulants within 7 days, non-vitamin K inhibitor anticoagulants within 72 hours, or heparin-derived compounds within 48 hours of treatment) - Participant has a known chronic viral infection such as Hepatitis B, Hepatitis C or HIV or has a known history of/active TB (Bacillus tuberculosis) - Subjects with evidence of cranial or systemic infection - Participant has received a solid organ or hematopoietic stem cell transplant - Participant has received a live vaccine within 28 days prior to the first dose of study agent Examples of live vaccines include, but are not limited to measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), typhoid vaccine, and intranasal influenza vaccines (e.g., FluMist®) - Participant has a severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study intervention - Known sensitivity to DEFINITY® ultrasound contrast agent or hypersensitivity to perflutren microsphere or its components, e.g., polyethylene glycol, as found in MiraLAX and bowel prep products - Contraindications to MRI and gadolinium-DTPA including non-MRI-compatible implanted devices, severe claustrophobia, unable to lie supine in MRI - Severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2, creatinine >1.5 ULN and/or on dialysis - Subjects with significant liver dysfunction, e.g., history of cirrhosis (hemochromatosis or severe alcohol abuse), or active hepatitis (autoimmune or infectious) with elevated AST, ALT INR or bilirubin (ALT: Male 21-72 units/L; Female 9-52 units/L; AST: Male 17-59 units/L, Female 14-36 units/L; INR >1.3; bilirubin >5 times lab normal) - Subject is currently enrolled in another intervention based clinical trial - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug - Has a known additional malignancy that is progressing or has required active treatment - Presence of leptomeningeal disease - Contraindications to pembrolizumab or has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients - Has a diagnosis of active autoimmune disease (e.g., irritable bowel syndrome, autoimmune Hepatitis, Guillain-Barre Syndrome, etc.) requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. History of (non-infectious) pneumonitis that requires steroids or has current pneumonitis - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator - Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Pembrolizumab with Exablate BBBD
Using Exablate Model 4000 Type 2 for the treatment of NSCLC brain metastases in subjects who are undergoing planned pembrolizumab monotherapy.
  • Device: Blood Brain Barrier Disruption - Oncology
    BBB opening via Exablate Type 2 system with microbubble resonators on the day of pembrolizumab infusion to treat brain metastases
    Other names:
    • Exablate BBBD
  • Drug: Pembrolizumab
    Pembrolizumab infusion
Active Comparator
Control Arm (Pembrolizumab only)
subjects will undergo planned pembrolizumab monotherapy.
  • Drug: Pembrolizumab
    Pembrolizumab infusion

Recruiting Locations

University of Maryland
Baltimore, Maryland 21201
Contact:
Kaitlyn Henry
410-328-0939
KHenry@som.umaryland.edu

More Details

Status
Recruiting
Sponsor
InSightec

Study Contact

Nadir Alikacem
+12146302000
nadira@insightec.com

Detailed Description

This is a prospective, multi-center, randomized, two-arm, controlled, pivotal clinical trial to evaluate the safety and efficacy of targeted blood brain barrier disruption using Exablate Model 4000 Type 2 for the treatment of NSCLC brain metastases in subjects who are undergoing planned pembrolizumab monotherapy for their primary disease. The study will be conducted at up to 20 centers in the US. The immunotherapy regimen (every 3 weeks for 6 cycles) of pembrolizumab is per the FDA approved labeling for pembrolizumab (Keytruda®) and the subjects prescribed standard of care therapy for their primary NSCLC. The study aims to demonstrate superiority of Exablate BBBD targeted to their brain metastases over the standard of care without Exablate BBBD with respect to the percentage of subjects achieving Objective Response Rate (ORR) by 6 months follow-up.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.